Terms: = Colorectal cancer AND FGFR2, BFR-1, 2263, ENSG00000066468, TK14, BEK, CD332, JWS, TK25, ECT1, CEK3, K-SAM, CFD1, KGFR AND Treatment
24 results:
1. Progress in clinical diagnosis and treatment of colorectal cancer with rare genetic variants.
Chen S; Gu J; Wu K; Zhao X; Lu Y
Cancer Biol Med; 2024 Jun; 21(6):473-83. PubMed ID: 38940668
[TBL] [Abstract] [Full Text] [Related]
2. PTPN9 dephosphorylates fgfr2 pY656/657 through interaction with ACAP1 and ameliorates pemigatinib effect in cholangiocarcinoma.
Zhao L; Liu J; Li K; Zhang C; Chen T; Liu Z; Tang Y; Hu X; Shi A; Shu L; Huang S; Lian S; Zhang M; Li H; Sun J; Yu X; Zhang Z; Zhang Z; Xu Y
Hepatology; 2024 Apr; 79(4):798-812. PubMed ID: 37505213
[TBL] [Abstract] [Full Text] [Related]
3. The Emerging Role of Circulating Tumor DNA in Non-colorectal Gastrointestinal cancers.
Lee MS; Kaseb AO; Pant S
Clin Cancer Res; 2023 Sep; 29(17):3267-3274. PubMed ID: 37092904
[TBL] [Abstract] [Full Text] [Related]
4. Genomic and transcriptomic analysis of MSI-H colorectal cancer patients with targetable alterations identifies clinical implications for immunotherapy.
Hua H; He W; Chen N; He Y; Wu G; Ye F; Zhou X; Li Y; Ding Y; Zhong W; Teng L; Jiang W; Sheng Q
Front Immunol; 2022; 13():974793. PubMed ID: 36700211
[TBL] [Abstract] [Full Text] [Related]
5. Clinical and molecular characteristics of kinase domain duplications across diverse cancer types in the Chinese population.
Lai X; Yu R; Ou Q; Bao H; Wu X; Shao Y; Li Y; Zhang Y; Ding Q
Cancer Med; 2023 Mar; 12(5):6009-6015. PubMed ID: 36325957
[TBL] [Abstract] [Full Text] [Related]
6. A novel patient-derived organoids-based xenografts model for preclinical drug response testing in patients with colorectal liver metastases.
Jian M; Ren L; He G; Lin Q; Tang W; Chen Y; Chen J; Liu T; Ji M; Wei Y; Chang W; Xu J
J Transl Med; 2020 Jun; 18(1):234. PubMed ID: 32532289
[TBL] [Abstract] [Full Text] [Related]
7. Overcoming Resistance to Targeted Therapies in Gastrointestinal cancers: Progress to Date and Progress to Come.
Chen C; Di Bartolomeo M; Corallo S; Strickler JH; Goyal L
Am Soc Clin Oncol Educ Book; 2020 May; 40():161-173. PubMed ID: 32421451
[TBL] [Abstract] [Full Text] [Related]
8. Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab.
Zhang H; Yuan L; Liu L; Yan C; Cheng J; Fu Q; Tong Z; Jiang W; Zheng Y; Zhao P; Zhang G; Fang W
BMC Cancer; 2020 May; 20(1):416. PubMed ID: 32404198
[TBL] [Abstract] [Full Text] [Related]
9. Molecularly annotation of mouse avatar models derived from patients with colorectal cancer liver metastasis.
Wang J; Xing B; Liu W; Li J; Wang X; Li J; Yang J; Ji C; Li Z; Dong B; Gao J; Shen L
Theranostics; 2019; 9(12):3485-3500. PubMed ID: 31281492
[No Abstract] [Full Text] [Related]
10. fgfr2 Promotes Expression of PD-L1 in colorectal cancer via the JAK/STAT3 Signaling Pathway.
Li P; Huang T; Zou Q; Liu D; Wang Y; Tan X; Wei Y; Qiu H
J Immunol; 2019 May; 202(10):3065-3075. PubMed ID: 30979816
[TBL] [Abstract] [Full Text] [Related]
11. Biologics, Immunotherapy, and Future Directions in the treatment of Advanced Cholangiocarcinoma.
Saeed A; Park R; Al-Jumayli M; Al-Rajabi R; Sun W
Clin Colorectal Cancer; 2019 Jun; 18(2):81-90. PubMed ID: 30905548
[TBL] [Abstract] [Full Text] [Related]
12. Clinical significance of multiple gene detection with a 22-gene panel in formalin-fixed paraffin-embedded specimens of 207 colorectal cancer patients.
Gao XH; Yu GY; Hong YG; Lian W; Chouhan H; Xu Y; Liu LJ; Bai CG; Zhang W
Int J Clin Oncol; 2019 Feb; 24(2):141-152. PubMed ID: 30612269
[TBL] [Abstract] [Full Text] [Related]
13. fgfr2 amplification is predictive of sensitivity to regorafenib in gastric and colorectal cancers in vitro.
Cha Y; Kim HP; Lim Y; Han SW; Song SH; Kim TY
Mol Oncol; 2018 Jun; 12(7):993-1003. PubMed ID: 29573334
[TBL] [Abstract] [Full Text] [Related]
14. Generation of high-affinity, internalizing anti-fgfr2 single-chain variable antibody fragment fused with Fc for targeting gastrointestinal cancers.
Borek A; Sokolowska-Wedzina A; Chodaczek G; Otlewski J
PLoS One; 2018; 13(2):e0192194. PubMed ID: 29420662
[TBL] [Abstract] [Full Text] [Related]
15. Role of fibroblast growth factor receptor-2 splicing in normal and cancer cells.
Ishiwata T
Front Biosci (Landmark Ed); 2018 Jan; 23(4):626-639. PubMed ID: 28930565
[TBL] [Abstract] [Full Text] [Related]
16. In vitro and in vivo evaluation of the radiosensitizing effect of a selective FGFR inhibitor (JNJ-42756493) for rectal cancer.
Verstraete M; Debucquoy A; Gonnissen A; Dok R; Isebaert S; Devos E; McBride W; Haustermans K
BMC Cancer; 2015 Dec; 15():946. PubMed ID: 26675289
[TBL] [Abstract] [Full Text] [Related]
17. Fibroblast growth factor receptor 2 overexpression is predictive of poor prognosis in rectal cancer patients receiving neoadjuvant chemoradiotherapy.
Li CF; He HL; Wang JY; Huang HY; Wu TF; Hsing CH; Lee SW; Lee HH; Fang JL; Huang WT; Chen SH
J Clin Pathol; 2014 Dec; 67(12):1056-61. PubMed ID: 25271212
[TBL] [Abstract] [Full Text] [Related]
18. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma.
Arai Y; Totoki Y; Hosoda F; Shirota T; Hama N; Nakamura H; Ojima H; Furuta K; Shimada K; Okusaka T; Kosuge T; Shibata T
Hepatology; 2014 Apr; 59(4):1427-34. PubMed ID: 24122810
[TBL] [Abstract] [Full Text] [Related]
19. Large-scale screening identifies a novel microRNA, miR-15a-3p, which induces apoptosis in human cancer cell lines.
Druz A; Chen YC; Guha R; Betenbaugh M; Martin SE; Shiloach J
RNA Biol; 2013 Feb; 10(2):287-300. PubMed ID: 23353574
[TBL] [Abstract] [Full Text] [Related]
20. Keratinocyte growth factor up-regulates Interleukin-7 expression following intestinal ischemia/reperfusion in vitro and in vivo.
Cai YJ; Wang WS; Liang HY; Sun LH; Teitelbaum DH; Yang H
Int J Clin Exp Pathol; 2012; 5(6):569-80. PubMed ID: 22949940
[TBL] [Abstract] [Full Text] [Related]
[Next]
